ReviewDrug safety2004
Communication of medical product risk: how effective is effective enough?
Review in Drug safety, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.Medical care · 2012Pooled it
- Impact of safety-related regulatory action on clinical practice: a systematic review.Drug safety · 2012Pooled it
- Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength.Hospital pharmacy · 2021Article
- Article
- Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.JAMA internal medicine · 2019Article
- Valproic acid utilization among girls and women in Stockholm: Impact of regulatory restrictions.Epilepsia open · 2018Article
- Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study.Drug safety · 2017Article
- Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).Drug safety · 2014Article
- The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals.European journal of clinical pharmacology · 2013Article
- Risk Communication and the Pharmaceutical Industry: what is the reality?Drug safety · 2012Article
- Focusing on risk communication about medicines: why now?Drug safety · 2012Article
- Drug vs class-specific black box warnings: does one bad drug spoil the bunch?Journal of general internal medicine · 2011Article
- Article
- Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.Drug safety · 2010Article
- A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.Drug safety · 2010Article
- Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.Drug safety · 2009Article
- Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
- Is there still a role for spontaneous reporting of adverse drug reactions?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ever-increasing attention is being paid worldwide to the safety of medical products, and the risks associated with their use. The integral role of risk communication in overall risk management is demonstrated by several recent market withdrawals of drugs, in which a perceived incapability of healthcare systems to manage well-characterised, avoidable risks was a significant factor. With advances in clinical pharmacology, pharmacogenomics and pharmacoepidemiology expanding our knowledge of medical products, effective delivery of the latest safety-related information to health professionals and consumers becomes even more imperative. In this regard, it is important to evaluate whether current modes of risk communication lead to desired changes in relevant behaviours such as prescribing or drug monitoring, particularly in context with which achieved level of effectiveness is deemed acceptable. This is crucial, as there have been product-specific risk communication efforts that achieved a fair degree of success, yet were not seen as effective enough to prevent market withdrawal of the medical product in question. In the service of improving public health through enhanced risk communication, it is essential to critically assess current methods, both as to results achieved (or not), and whether each method is applicable to the various types of risks associated with medical product use. Furthermore, just as combining methods may well improve overall risk communication, there are societal and psychological factors that must be considered in attempting to maximise effectiveness. However, in assessing risk communication effectiveness, the particular benefit- risk relationship of any individual medical product must also be part of the evaluative process.
Indexed as
Identifiers
15154825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.